This strategic alliance is aimed at strengthening hospital systems and developing advanced AMR interventions
The emergence of new infections in India is a growing concern
Project achieves 30% reduction in hospital acquired infections and 24% reduction in the incidence of multi-drug resistant organisms
Antimicrobial Resistance (AMR) poses a significant threat to global healthcare systems and patient safety
The conference is also expected to pave the way for nations to come out with bold and specific political commitments in the 2024 UN General Assembly High-Level Meeting on AMR
The JV is funded by Boehringer Ingelheim as lead investor with 30 million EUR and by Evotec and bioMérieux with 5 million EUR each.
The meeting was co-organized by World Health Organization’s Country Office for India, World Animal Protection India and ReAct Asia Pacific
MET-X, a novel metallo-beta-lactamase (MBL) inhibitor, has shown best-in-class performance in preclinical studies
EMBLAVEOTM is the first and only monobactam/?-lactamase inhibitor combination antibiotic therapy approved by the USFDA
The overall clinical efficacy of Zaynich across indications was 98% at the test-of-cure
Subscribe To Our Newsletter & Stay Updated
